The DOI matches its Crossref record.
Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS—We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS—Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4% vs. 40.9 ± 31.9%, P = 0.004) compared with the control group. CONCLUSIONS—We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 36
- Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517–529, 2001 · DOI · Paper page
- Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS: Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 118:344–349, 1993 · DOI · Paper page
- Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG: Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 35:1554–1559, 2000 · DOI
- Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J: Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 34:1498–1506, 1999 · doi:10.1016/s0735-1097(99)00366-6
- Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496–501, 1994 · DOI · Paper page
- Mudra H, di Mario C, de Jaegere P, Figulla HR, Macaya C, Zahn R, Wennerblom B, Rutsch W, Voudris V, Regar E, Henneke KH, Schachinger V, Zeiher A, OPTICUS (OPTimization with ICUS to reduce stent restenosis) Study Investigators: randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS study). Circulation 104:1343–1349, 2001 · DOI · Paper page
- Moses JW, Moussa I, Leon MB, Teirstein PS, Fish RD, Ellis SG, Nawas D, Kluck B, Giorgianni JA, Donohoe D, Kuntz RE: Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I randomized trial). Am J Cardiol 90:243–247, 2002 · doi:10.1016/s0002-9149(02)02462-1
- Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665–1671, 1998 · DOI · Paper page
- Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318:1714–1719, 1988 · DOI · Paper page
- O’Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 342:1316–1324, 2000 · DOI · Paper page
- Gimple LW, Herrmann HC, Winniford M, Mammen E: Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 83:1524–1529, 1999 · doi:10.1016/s0002-9149(99)00141-1
- Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, the Troglitazone Study Group: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433–439, 1997 · DOI · Paper page
- Tack CJ, Smits P, Demacker PN, Stalenhoef AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796–799, 1998 · DOI
- Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD, Rosiglitazone Study 108 Investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952, 2002 · DOI · Paper page
- Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684, 2002 · DOI · Paper page
- Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818–1820, 1998 · doi:10.1210/jcem.83.5.4932 · Paper page
- Takagi T, Akasaka T, Yamamuro A, Honda, Hozumi T, Morioka S, Yoshida K: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 36:1529–1539, 2000 · DOI · Paper page
- Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, Akasaka T, Yoshida K: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89:318–322, 2002 · doi:10.1016/s0002-9149(01)02232-9
- Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:E5, 2003 · DOI
- Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB: Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 95:1366–1369, 1997 · DOI · Paper page
- Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB: Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 94:1247–1254, 1996 · DOI · Paper page
- Teirstein PS, Massullo V, Jani S, Popma JJ, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Sirkin K, Cloutier DA, Leon MB, Tripuraneni P: Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 101:360–365, 2000 · doi:10.1161/01.cir.101.4.360
- Raizner AE, Oesterle SN, Waksman R, Serruys PW, Colombo A, Lim YL, Yeung AC, van der Giessen WJ, Vandertie L, Chiu JK, White LR, Fitzgerald PJ, Kaluza GL, Ali NM: Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 102:951–958, 2000 · doi:10.1161/01.cir.102.9.951
- Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS: A paclitaxel-eluting stent for the prevention of coronary stenosis. N Engl J Med 348:1537–1545, 2003 · DOI · Paper page
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780, 2002 · DOI · Paper page
- Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661–1669, 1996 · DOI
- Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101:1311–1318, 2000 · DOI · Paper page
- Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 95:7614–7619, 1998 · DOI · Paper page
- Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897–1905, 1996 · DOI · Paper page
- Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401:259–270, 2000 · DOI
- Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF: Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147:E23, 2004 · DOI
- Kitamoto S, Egashira K, Takeshita A: Stress and vascular responses: anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention. J Pharmacol Sci 91:192–196, 2003 · doi:10.1254/jphs.91.192
- Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W: Effect of rosiglitazone treatment on soluble CD40L inpatients with type 2 diabetes and coronary artery disease. Circulation 107:1954–1957, 2003 · DOI · Paper page
- Marx N, Froehlich, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283–288, 2003 · DOI · Paper page
- Ishbashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40:687–693, 2002 · DOI
- Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 27:1647–1653, 2004 · DOI · Paper page
Cited by
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 757
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 579
Thiazolidinediones: the forgotten diabetes medications
Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388
Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Meigs, J. B., Bonadonna, R. C., & Muggeo, M. (2007) · Diabetes Care · doi:10.2337/dc06-0919 · Cited by 343
Metadata
- Authors
- Choi, D., Kim, S.-K., Choi, S.-H., Ko, Y.-G., Ahn, C.-W., Jang, Y., Lim, S.-K., Lee, H.-C., & Cha, B.-S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 2654-2660
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1977390060
- Cited by
- 243
- References
- 0
- FWCI
- 38.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.27.11.2654
- The paper
- Choi, D., Kim, S.-K., Choi, S.-H., Ko, Y.-G., Ahn, C.-W., Jang, Y., Lim, S.-K., Lee, H.-C., & Cha, B.-S. (2004). Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.27.11.2654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.